|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Cash flows from operating activities | |||||
| Net loss | |||||
| Adjustments to reconcile net loss to net cash used in operating activities: | |||||
| Depreciation and amortization | |||||
| Loss on disposal of property and equipment | |||||
| Loss on impairment of operating right-of-use assets and related property and equipment | |||||
| Accretion of discounts and amortization of premiums on marketable securities, net | |||||
| Non-cash lease expense | |||||
| Loss (gain) on long-term investments, net | |||||
| Change in fair value of preferred stock warrants | |||||
| Share-based compensation expense | |||||
| Gain on ROU asset abandonment | |||||
| Loss on sale/ disposal of assets | |||||
| Impairment of assets | |||||
| Changes in operating assets and liabilities: | |||||
| Accounts receivable, net | |||||
| Inventory | |||||
| Prepaid expenses and other current assets | |||||
| Accounts payable | |||||
| Accrued compensation | |||||
| Accrued research costs | |||||
| Accrued expenses and other current liabilities and other liabilities | |||||
| Operating lease liabilities | |||||
| Accrued liabilities | |||||
| Other assets | |||||
| Net cash used in operating activities | |||||
| Cash flows from investing activities | |||||
| Purchases of marketable securities | |||||
| Proceeds from maturities of marketable securities | |||||
| Purchases of property and equipment | |||||
| Proceeds from sales of property and equipment | |||||
| Purchases of investments in marketable securities | |||||
| Proceeds from sales and maturities of marketable securities | |||||
| Net cash used in investing activities | |||||
| Cash flows from financing activities | |||||
| Proceeds from issuance of Series B convertible preferred stock, net of issuance costs | |||||
| Deferred offering costs | |||||
| Proceeds from issuance of common stock, net of issuance costs | |||||
| At The Market Offerings | |||||
| PIPE Financing | |||||
| Total proceeds from issuance of common stock, net of issuance costs | |||||
| Proceeds from exercises of stock options | |||||
| Proceeds from issuance of common stock under employee stock purchase plan | |||||
| Repurchase of unvested early exercised shares and founders' shares | |||||
| Cash, cash equivalents, and restricted cash acquired in connection with the Merger | |||||
| Merger transaction costs | |||||
| Net cash provided by financing activities | |||||
| Net increase (decrease) in cash, cash equivalents, and restricted cash | |||||
| Cash, cash equivalents and restricted cash, at beginning of period | |||||
| Cash, cash equivalents and restricted cash, at end of period | |||||
| Cash and cash equivalents | |||||
| Restricted cash | |||||
| Cash, cash equivalents, and restricted cash, beginning of the period | |||||
| Cash, cash equivalents, and restricted cash, end of the period | |||||
| Supplemental cash flow information | |||||
| Conversion of stock to common stock | |||||
| Conversion of Series A, A-1, and B convertible preferred stock to common stock | |||||
| Conversion of Class B convertible common stock to common stock | |||||
| Property and equipment purchases in accounts payable and accrued expenses | |||||
| Lessor funded lease incentives included in property and equipment | |||||
| Additions to ROU assets from new operating lease liabilities | |||||
| Vesting of early exercised stock options | |||||
| Repurchase of unvested early exercised shares included in accounts payable | |||||
| Reclassification of warrant liability to equity | |||||
| Prepaid expenses and other current assets assumed in the Merger | |||||
| Accounts payable and accrued liabilities assumed in the Merger | |||||
| Right-of-use assets assumed in the Merger in exchange for operating lease liabilities | |||||
| Right-of-use assets obtained in exchange for operating lease liabilities | |||||
| Property and equipment included in accounts payable and accrued expenses | |||||
| Deferred offering costs included in accounts payable and accrued expenses | |||||
Loading...